ATE398126T1 - Azaindolinhibitoren von mtp und apob - Google Patents

Azaindolinhibitoren von mtp und apob

Info

Publication number
ATE398126T1
ATE398126T1 AT05754288T AT05754288T ATE398126T1 AT E398126 T1 ATE398126 T1 AT E398126T1 AT 05754288 T AT05754288 T AT 05754288T AT 05754288 T AT05754288 T AT 05754288T AT E398126 T1 ATE398126 T1 AT E398126T1
Authority
AT
Austria
Prior art keywords
azaindolin
hibitors
apob
mtp
azaindolin hibitors
Prior art date
Application number
AT05754288T
Other languages
English (en)
Inventor
Alyx Guevel
Catherine Vidal
Bruno Roux
Olivier Chevreuil
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE398126T1 publication Critical patent/ATE398126T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05754288T 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob ATE398126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408302A FR2873694B1 (fr) 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob

Publications (1)

Publication Number Publication Date
ATE398126T1 true ATE398126T1 (de) 2008-07-15

Family

ID=34948943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05754288T ATE398126T1 (de) 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob

Country Status (16)

Country Link
US (1) US7838533B2 (de)
EP (1) EP1771446B1 (de)
JP (1) JP5161569B2 (de)
AR (1) AR050436A1 (de)
AT (1) ATE398126T1 (de)
AU (1) AU2005266662B2 (de)
CA (1) CA2575223C (de)
CY (1) CY1108306T1 (de)
DE (1) DE602005007494D1 (de)
DK (1) DK1771446T3 (de)
ES (1) ES2308510T3 (de)
FR (1) FR2873694B1 (de)
PL (1) PL1771446T3 (de)
PT (1) PT1771446E (de)
SI (1) SI1771446T1 (de)
WO (1) WO2006010423A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201100812A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2268811A1 (de) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
EP2470552B1 (de) 2009-08-26 2013-11-13 Sanofi Neuartige kristalline heteroaromatische Fluorglycosidhydrate, Pharmazeutika, die diese Verbindungen umfassen, und deren Verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012177782A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
KR101931089B1 (ko) 2013-06-27 2019-03-14 로슈 이노베이션 센터 코펜하겐 에이/에스 Pcsk９ 를 표적화하는 안티센스 올리고머 및 접합체
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
BR0210616A (pt) * 2001-06-28 2004-09-28 Pfizer Prod Inc Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
JPWO2003101983A1 (ja) * 2002-05-31 2005-09-29 アステラス製薬株式会社 テトラヒドロピラン誘導体
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
JP4737495B2 (ja) * 2004-01-14 2011-08-03 塩野義製薬株式会社 エリスロマイシン誘導体

Also Published As

Publication number Publication date
DK1771446T3 (da) 2008-09-22
PL1771446T3 (pl) 2008-10-31
PT1771446E (pt) 2008-09-17
WO2006010423A3 (en) 2006-03-02
AU2005266662B2 (en) 2011-04-21
US20090036481A1 (en) 2009-02-05
DE602005007494D1 (de) 2008-07-24
ES2308510T3 (es) 2008-12-01
JP2008508198A (ja) 2008-03-21
WO2006010423A2 (en) 2006-02-02
FR2873694B1 (fr) 2006-12-08
US7838533B2 (en) 2010-11-23
CY1108306T1 (el) 2014-02-12
AU2005266662A1 (en) 2006-02-02
EP1771446B1 (de) 2008-06-11
JP5161569B2 (ja) 2013-03-13
CA2575223C (en) 2013-08-06
FR2873694A1 (fr) 2006-02-03
AR050436A1 (es) 2006-10-25
CA2575223A1 (en) 2006-02-02
SI1771446T1 (sl) 2008-10-31
EP1771446A2 (de) 2007-04-11

Similar Documents

Publication Publication Date Title
ATE398126T1 (de) Azaindolinhibitoren von mtp und apob
DE602005011285D1 (de) Formmasse von polymer
DE602005019971D1 (de) Inhibitoren von cysteinprotease
DE602005012825D1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE521604T1 (de) N-substituierte benzimidazolyl-c-kit-inhibitoren und kombinatorische benzimidazolbibliothek
ATE557025T1 (de) Inhibitoren von dipeptidylpeptidase iv auf pyrrolopyridinbasis und verfahren
DE602004005753D1 (de) Kombinationen von harzzusammensetzungen und verwendungsverfahren dafür
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE410421T1 (de) P38 inhibitor und anwendungsverfahren dafür
ATE493421T1 (de) Neue inhibitoren von chymase
DE602005015382D1 (de) Effektives und robustes Routing unabhängig von Verkehrsänderungen
DE602005007987D1 (de) achtelung und -entschachtelung
DE502005006286D1 (de) Verwendung von trisubstituierten benzopyranonen
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
FI20030261A (fi) Iskulaite
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
DE602005012674D1 (de) Nachweiselement und nachweisverfahren
ATE499096T1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
DE602007012260D1 (de) Nitratester von piperidinen
ATE468342T1 (de) Azolopyridin-2-on-derivate als inhibitoren von lipasen und phospholipasen
ATE495163T1 (de) Benzothiazol-2-on-derivate als inhibitoren von lipasen und phospholipasen
DE602005001066D1 (de) Komplexe Emulsionen von Perfluoropolyethern
ATE409477T1 (de) Kombination von voriconazol und einem antifungalen cyp2c19-inhibitor
DE112004002972A5 (de) Gefederter und zusammenlegbarer Schlitten
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1771446

Country of ref document: EP